https://www.aurontx.com https://www.aurontx.com/about https://www.aurontx.com/science https://www.aurontx.com/news https://www.aurontx.com/join-us https://www.aurontx.com/contact https://www.aurontx.com/programs-and-pipeline https://www.aurontx.com/news/auron-announces-first-patient-dosed-in-phase-1-clinical-trial-of-autx-703-in-advanced-hematologic-malignancies https://www.aurontx.com/news/auron-announces-oral-presentation-on-preclinical-data-from-proprietary-aurigin-tm-platform-at-the-ai-in-biomedicine-keystone-symposia https://www.aurontx.com/news/auron-announces-poster-presentation-at-2024-pcf-annual-scientific-retreat https://www.aurontx.com/news/auron-announces-poster-presentations-at-2024-aacr-annual-meeting https://www.aurontx.com/news/auron-establishes-premier-scientific-advisory-board-to-support-the-advancement-of-its-ai-powered-platform-and-pipeline-targeting-cellular-plasticity-in-cancer https://www.aurontx.com/news/auron-presents-new-preclinical-data-for-autx-703-in-aml-at-ash-annual-meeting https://www.aurontx.com/news/auron-presents-new-preclinical-data-for-autx-703-in-small-cell-lung-cancer-sclc https://www.aurontx.com/news/auron-presents-new-preclinical-data-for-lead-program-autx-703-across-multiple-cancer-types https://www.aurontx.com/news/auron-presents-preclinical-data-at-american-chemical-society-annual-meeting https://www.aurontx.com/news/auron-presents-preclinical-data-highlighting-the-activity-of-autx-703-in-prostate-cancer-at-2025-aacr-annual-meeting https://www.aurontx.com/news/auron-selects-first-development-candidate-for-its-portfolio-of-next-generation-targeted-cancer-treatments-from-its-novel-aurigin-tm-platform https://www.aurontx.com/news/auron-strengthens-board-of-directors-and-leadership-team-with-industry-veterans-victoria-richon-ph-d-and-christopher-guiffre-j-d-mba https://www.aurontx.com/news/auron-therapeutics-announces-48-million-series-a-financing-to-drive-novel-oncology-pipeline-leveraging-a-machine-learning-multi-omics-based-platform https://www.aurontx.com/news/auron-therapeutics-announces-autx-703-granted-fast-track-designation-by-the-fda-for-relapsed-or-refractory-acute-myelogenous-leukemia https://www.aurontx.com/news/auron-therapeutics-announces-fda-clearance-to-initiate-clinical-development-of-autx-703-and-completion-of-series-b-financing https://www.aurontx.com/news/auron-therapeutics-announces-poster-presentation-at-2025-aacr-annual-meeting https://www.aurontx.com/news/auron-therapeutics-closes-12-75-million-seed-financing-to-develop-differentiation-therapies-for-treatment-of-cancers https://www.aurontx.com/news/auron-therapeutics-expands-leadership-with-appointment-of-glenn-goddard-as-chief-financial-officer https://www.aurontx.com/news/auron-therapeutics-to-participate-in-the-8th-annual-targeted-protein-degradation-induced-proximity-summit https://www.aurontx.com/news/auron-to-present-autx-703-preclinical-data-2024-ena-symposium https://www.aurontx.com/news/auron-to-present-new-preclinical-data-for-autx-703-at-2024-ash-meeting https://www.aurontx.com/news/auron-unveils-preclinical-data-supporting-its-lead-program-and-ability-of-its-aurigin-tm-platform-to-generate-targeted-cancer-therapies-at-aacr-annual-meeting https://www.aurontx.com/careers/medical-director-senior-medical-director https://www.aurontx.com/legal/privacy-policy https://www.aurontx.com/legal/terms-of-use